Mungo Park
Direktor/Vorstandsmitglied bei PDS LIMITED
Profil
Mungo Park is the founder of Innovator Capital Ltd.
which was founded in 2003, where he holds the title of Chairman.
He is also the founder of Prince Albert II of Monaco Foundation.
Currently, Mr. Park holds the position of Independent Non-Executive Director at PDS Ltd.
since 2021 and is a Member of The Group of Eight Ltd.
Mr. Park's former positions include Chairman at Heart Metabolics Ltd., Independent Director at CDTi Advanced Materials, Inc., and Head-Corporate Finance at Nomura Holding America, Inc.
Aktive Positionen von Mungo Park
| Unternehmen | Position | Beginn |
|---|---|---|
| PDS LIMITED | Direktor/Vorstandsmitglied | 09.11.2021 |
Innovator Capital Ltd.
 Innovator Capital Ltd. Investment ManagersFinance Innovator Capital Ltd. provides investment bank advisory services. It specializes in advising emerging Cleantech, ICT and Life Science companies. The firm provides expert strategic and capital markets advice, transaction arranging, M&A and intellectual property services for private and public companies. Its offers corporate finance, M&A - in/out licensing, ip strategy, media strategy and policy technology advisory services. The company was founded by Mungo Park in 2003 and is headquartered in London, the United Kingdom. | Gründer | 01.01.2003 |
| Prince Albert II of Monaco Foundation | Gründer | - |
| The Group of Eight Ltd | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Mungo Park
| Unternehmen | Position | Ende |
|---|---|---|
Heart Metabolics Ltd.
 Heart Metabolics Ltd. BiotechnologyHealth Technology Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland. | Vorsitzender | - |
Nomura Holding America, Inc.
 Nomura Holding America, Inc. Investment Banks/BrokersFinance Nomura Holding America, Inc. provides investment banking and securities services. It operates in North and South America and deals with equities, fixed income, asset management, venture capital and private equity investing. The company was founded in 1989 and is headquartered in New York, NY. | Finanzdirektor/CFO | - |
| CDTI ADVANCED MATERIALS, INC. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CDTI ADVANCED MATERIALS, INC. | Producer Manufacturing |
| PDS LIMITED | Consumer Non-Durables |
| Private Unternehmen | 4 |
|---|---|
Nomura Holding America, Inc.
Nomura Holding America, Inc. Investment Banks/BrokersFinance Nomura Holding America, Inc. provides investment banking and securities services. It operates in North and South America and deals with equities, fixed income, asset management, venture capital and private equity investing. The company was founded in 1989 and is headquartered in New York, NY. | Finance |
Innovator Capital Ltd.
Innovator Capital Ltd. Investment ManagersFinance Innovator Capital Ltd. provides investment bank advisory services. It specializes in advising emerging Cleantech, ICT and Life Science companies. The firm provides expert strategic and capital markets advice, transaction arranging, M&A and intellectual property services for private and public companies. Its offers corporate finance, M&A - in/out licensing, ip strategy, media strategy and policy technology advisory services. The company was founded by Mungo Park in 2003 and is headquartered in London, the United Kingdom. | Finance |
| Prince Albert II of Monaco Foundation | Miscellaneous |
Heart Metabolics Ltd.
Heart Metabolics Ltd. BiotechnologyHealth Technology Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland. | Health Technology |
